Repligen | RGEN - 营业利润



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.28B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


营业利润 更改 日
Agilent USD 399M 46M 2026-03
Align Technology USD 191.32M 13.27M 2026-06
Bio Techne USD 75.49M 21.03M 2026-03
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Bruker USD 69.6M 59.4M 2026-06
Charles River Laboratories USD 119.89M 9K 2026-06
Danaher USD 1.13B 217M 2026-06
Dentsply International USD 84M 52M 2026-06
General Electric Aerospace USD 2.32B 549M 2026-03
Henry Schein USD 200M 18M 2026-06
Illumina USD 260M 21M 2026-06
IQVIA Holdings USD 2.6B 2.03B 2026-06
Mettler Toledo International USD 287.55M 53.61M 2026-06
Myriad Genetics USD -3M 20.3M 2025-12
OraSure Technologies USD -13.59M 2.13M 2025-12
Pacific Biosciences Of California USD -53.19M 35.08M 2025-12
Pfizer USD 667M 4.32B 2026-06
Repligen USD 21.13M 1.15M 2026-06
Revvity USD 126.14M 43.36M 2026-06
Standard Biotools USD -9.42M 12.51M 2026-03
Thermo Fisher Scientific USD 2.18B 273M 2026-06
Waters USD -86M 234M 2026-06
West Pharmaceutical Services USD 179.1M 2M 2026-06